Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-26528398 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JNJ-26528398 | DRUG | In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1. |
| Placebo | DRUG | In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days. |
Inclusion Criteria: * Nonsmoker * Be in good health on the basis of physical examination, medical history, and electrocardiogram (ECG) * Must have good exercise tolerance * Have a body mass index of 18-29 kg/m2, inclusive, and body weight between 60 and 85 kg, inclusive * Have a history of consiste...
JNJ-26528398 is an investigational small molecule drug developed by Johnson & Johnson. It has been studied in a Phase 1 clinical trial in healthy male participants. No approved indication has been announced for JNJ-26528398, and it remains in early clinical development.
JNJ-26528398 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 study of the compound conducted in Belgium.
JNJ-26528398 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials of JNJ-26528398 are currently listed.
JNJ-26528398 has been evaluated in one completed Phase 1 trial, NCT01520142, titled Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants. The trial enrolled 19 healthy male volunteers aged 18 years and older in Belgium and was randomized, double-blind, and placebo-controlled.
The Phase 1 trial NCT01520142 assessed the safety, tolerability, and pharmacodynamic activity of JNJ-26528398 in healthy male participants. It enrolled 19 participants in Belgium and used a randomized, double-blind, placebo-controlled design. The study has been completed.